Cohorts 1-8 will include 60 QFT-negative (Cohorts 1-4) and 60 QFT-positive (Cohorts 5-8) participants. Participants will be randomized within each cohort, to receive either MTBVAC (N=96) or BCG (N=24). The cohorts will be enrolled as described in the protocol, as long as no pausing/stopping rules are triggered